BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Elpiscience (Suzhou) Biopharma\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Elpiscience (Suzhou) Biopharma\, 
 Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06623136-2546@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ordastobart: Phase 2 readout est. (NCT06623136)
DESCRIPTION:Ordastobart\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of ES102 in Combination With Toripalimab in Subjects With Advanced No
 n-small Cell Lung Cancer\nEstimated primary completion: 28 February 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06623136
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295731-2546@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ordastobart: Phase 2/3 readout est. (NCT06295731)
DESCRIPTION:Ordastobart\, phase 2/3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1
 + R/M OPSCC (HexAgon-HN)\nEstimated primary completion: December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06295731
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-2546@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Ordastobart: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Ordastobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytrud
 a®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexaval
 ent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
